Dare Bioscience, Inc.
Dare Bioscience, Inc. is listed today as Daré Bioscience, Inc.: market value, financials and filings are on its company page.
Funding rounds
6 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $12 M | Private placement after listing | $10 to $50 million | options | SEC | |
| Dec 2023 | $2 M | Private placement after listing | Under $2 million | options | SEC | |
| Nov 2019 | $4 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Jul 2017 | $21 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Nov 2012 | $13 M | No. 6 | $10 to $50 million | equity | SEC | |
| Dec 2011 | $15 M | No. 5 | $10 to $50 million | equity, options | SEC | |
| Nov 2010 | $17 M | No. 4 | $10 to $50 million | equity | SEC | |
| Sep 2010 | $2 M | No. 3 | Under $2 million | debt, options | SEC | |
| May 2010 | $5 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Jul 2009 | $10 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Daré Bioscience, Inc., its revenue in fiscal 2025 came from these product and service lines: License fee revenue and other revenue $1.03 million (100%).
Annual report (SEC XBRL) · Dec 2025
Dare Bioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2026).
SEC Form D · Aug 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2026
Products and services#
No products or services of Dare Bioscience, Inc. are on record.
Investors#
24 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| CVF LLC | Other | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lilly Eli & Co | Other | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lilly Ventures Fund I LLC | Venture capital | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lux Capital Management, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lux Venture Associates II, LLC | Venture capital | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lux Venture Partners II, L.P. | Venture capital | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lux Ventures II, L.P. | Venture capital | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lux Ventures II Partners Fund I LLC | Venture capital | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lux Ventures II Sidecar LP | Venture capital | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Management Co IV LLC | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Management Co. V, L.L.C. | Venture capital | not stated | not stated | Held Series B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Partners Entrepreneurs Fund IV LP | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Partners Entrepreneurs' Fund V, L.P. | Venture capital | not stated | not stated | Held Series B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Partners Founders' Fund V, L.P. | Venture capital | not stated | not stated | Held Series B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Partners IV LP | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Partners Special Founders' Fund V, L.P. | Venture capital | not stated | not stated | Held Series B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Partners V, L.P. | Venture capital | not stated | not stated | Held Series B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| VEF Management V, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Venrock Associates V LP | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Venrock Entrepreneurs Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Venrock Management V, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Venrock Partners Management V, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Venrock Partners V L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| William H. Rastetter | Person | not stated | not stated | Held Series A, B, B-1, C and D preferred stock, director (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 19 investors.
Largest shareholders today
Institutions holding Daré Bioscience, Inc. shares, as of Sep 30, 2026.
- Vanguard Capital Management LLC$1 M4.14%
- UBS Group AG$0 M1.57%
- US Bancorp \de\$0 M1.44%
- Geode Capital Management, LLC$0 M1.00%
- Vanguard Fiduciary Trust Co$0 M0.60%
- BlackRock, Inc.$0 M0.41%
- State Street Corp$0 M0.31%
- Citadel Advisors LLC$0 M0.30%
- XTX Topco Ltd$0 M0.24%
- HRT Financial LP$0 M0.24%
- Northern Trust Corp$0 M0.22%
- Virtu Financial LLC$0 M0.22%
- Two Sigma Securities, LLC$0 M0.13%
- Garde Capital, Inc.$0 M0.11%
- LPL Financial LLC$0 M0.10%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| MarDee Martucci Haring-Layton | Chief Accounting Officer | Aug 2026 |
| Sabrina Martucci Johnson | President and Chief Executive Officer | Aug 2026 |
| Lisa Martucci Walters-Hoffert | Executive officer | Dec 2023 |
| Lisa H. Walters-Hoffert | Executive officer | Jul 2017 |
| Alexandra E. Glucksmann | Executive officer | Dec 2012 |
| Christopher D.T. Guiffre | Executive officer | Dec 2012 |
| Edward E. Garmey | Executive officer | Dec 2012 |
| Jean E. Silveri | Executive officer | Dec 2012 |
| Karen E. Roberts | Executive officer | Dec 2012 |
| Oliver Fetzer | Executive officer | Dec 2012 |
| Alexandra P. Glucksmann | Executive officer | Dec 2011 |
| David P. DeMagistris | Executive officer | Dec 2011 |
| Edward P. Garmey | Executive officer | Dec 2011 |
| Jean P. Silveri | Executive officer | Dec 2011 |
| Karen P. Roberts | Executive officer | Dec 2011 |
| John P. Ryan | Executive officer | Nov 2010 |
| Alexandra Glucksmann | Executive officer | Oct 2010 |
| Gregory W. Matz | Director | Aug 2026 |
| Jessica D. Grossman | Director | Aug 2026 |
| Robin J. Steele | Director | Aug 2026 |
| Sabrina Martucci Johnson | President and Chief Executive Officer | Aug 2026 |
| Susan L. Kelley | Director | Aug 2026 |
| William H. Rastetter | Director | Aug 2026 |
| Cheryl R. Blanchard | Director | Dec 2023 |
| Sophia N. Ononye-Onyia | Director | Dec 2023 |
| Cheryl J. Blanchard | Director | Sep 2021 |
| Roger L. Hawley | Director | Jul 2017 |
| Alan Crane | Director | Dec 2012 |
| Bryan E. Roberts | Director | Dec 2012 |
| Oliver Fetzer | Director | Dec 2012 |
| Ram E. Sasisekharan | Director | Dec 2012 |
| Robert E. Paull | Director | Dec 2012 |
| Robert E. Tepper | Director | Dec 2012 |
| Steven E. Hall | Director | Dec 2012 |
| Alan E. Crane | Director | Oct 2010 |
| Robert E. Langer | Director | Oct 2010 |
| Ram Sasisekharan | Director | Jul 2009 |
| Robert Langer | Director | Jul 2009 |
| Robert Tepper | Director | Jul 2009 |
| Terry McGuire | Director | Jul 2009 |
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.